Enhancement of drug delivery in prostate tumor in vivo using MR guided focused ultrasound (MRgHIFU)

IFMBE Proceedings

Volumn 25, Issue 6, 2009, Pages 341-344

  Chen, Lili ^a   Mu, Z ^a   Hachem, P ^a   Ma, C M ^a   Pollack, A ^b  

^a FOX CHASE CANCER CENTER   (United States)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

Drug delivery; In vivo; Mouse model; MRgHIFU; Prostate cancer

Indexed keywords

BIOMEDICAL ENGINEERING; CONTROLLED DRUG DELIVERY; DISEASES; DRUG DELIVERY; ENDOSCOPY; MAMMALS; MEDICAL IMAGING; MEDICAL PHYSICS; SURGERY; TARGETED DRUG DELIVERY; TUMORS; ULTRASONICS; UROLOGY;

FOCUSED ULTRASOUND; GENERAL ANESTHESIAS; HUMAN PROSTATE CANCER; IN-VIVO; LIQUID SCINTILLATION COUNTER; MOUSE MODELS; MRGHIFU; PROSTATE CANCERS;

DRUG PRODUCTS;

EID: 77949393612     PISSN: 16800737     EISSN: None     Source Type: Conference Proceeding    
DOI: 10.1007/978-3-642-03906-5_94     Document Type: Conference Paper

References (6)

1. R Stoyanova, P Hachem, H Hensley et al.(2007) Antisense MDM2 Sensitizes LNCaP Prostate Cancer Cells to Androgen Deprivation, Radiation and the Combination in vivo. Int J Radiat Oncol Biol Phys. 68(4):1151-1160
2. Banerjee S, Hussain M and Wang Z et al. (2007) In vitro and in vivo molecular evidence for better therapeutic efficacy of ABT-627 and taxotere combination in prostate cancer. Cancer Res. 67:3818-26
3. Wu JD, Haugk K, Coleman I et al. (2006) Combined in vivo effect of A12, a type 1 insulin-like growth factor receptor antibody, and docetaxel against prostate cancer tumors. Clin Cancer Res. 12:6153-60
4. 3H]-docetaxel in faeces and urine: development and validation of a novel combustion method. Anticancer Drugs. 17: 63-67
5. Yuh EL, Shulman SG, Mehta SA, Xie J, Chen L, Frenkel V, Bednarski MD and Li KCP. Delivery of a Systemic Chemotherapeutic Agent to Tumors Using Focused Ultrasound: study in a murine model Radiology 234(2): 431 - 437 (2005)
6. Chen L, Hachem P, Hananel A et al. (2007) MR guided focused ultra-sound (MRgFU) for the treatment of prostate cancer: A feasibility study of increasing cellular uptake of AS-MDM2 in vivo. Medical Physics, 34: 2625.